GENETIX Pharmaceuticals Garners $35,000,000 Series B Round

  • Feed Type
  • Date
    3/12/2010
  • Company Name
    GENETIX Pharmaceuticals
  • Mailing Address
    840 Memorial Drive Cambridge, MA 02139
  • Company Description
    GENETIX’ LentiGlobin hemoglobin gene therapy utilizes a highly modified human lentivirus to deliver a corrective version of the native beta-globin gene to the chromosomes of blood stem cells, found in large numbers in bone marrow.
  • Website
    http://www.genetixpharm.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $35,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the financing will be used to advance current clinical programs, strengthen platform capabilities and further expand the team.
  • M&A Terms
  • Venture Investor
    Third Rock Ventures
  • Venture Investor
    Genzyme Ventures
  • Venture Investor
    TVM Capital
  • Venture Investor
    Forbion Capital Partners
  • Venture Investor
    Easton Hunt Capital Partners

By posting a comment, you agree to our terms and conditions.